Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0L7IZ
|
|||
| Former ID |
DIB020118
|
|||
| Drug Name |
JP1302
|
|||
| Synonyms |
N-(4-(4-Methyl-1-piperazinyl)phenyl)-9-acridinamine; GNF-PF-3427; TCMDC-123912; BRN 5117597; 80259-18-3; MMV006172; JP 1302; N-[4-(4-methylpiperazin-1-yl)phenyl]acridin-9-amine; CHEMBL106525; QZKGUNQLVFEEBA-UHFFFAOYSA-N; 9-Acridinamine, N-(4-(4-methyl-1-piperazinyl)phenyl)-; Acridin-9-yl-[4-(4-methyl-piperazin-1-yl)-phenyl]-amine; N-(4-(4-methylpiperazin-1-yl)phenyl)acridin-9-amine; N-[4-(4-Methyl-1-piperazinyl)phenyl]-9-acridinamine; 9-Acridinamine, N-[4-(4-methyl-1-piperazinyl)phenyl]-; JP-1302; JP-1302
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1], [2] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C24H24N4
|
|||
| Canonical SMILES |
CN1CCN(CC1)C2=CC=C(C=C2)NC3=C4C=CC=CC4=NC5=CC=CC=C53
|
|||
| InChI |
1S/C24H24N4/c1-27-14-16-28(17-15-27)19-12-10-18(11-13-19)25-24-20-6-2-4-8-22(20)26-23-9-5-3-7-21(23)24/h2-13H,14-17H2,1H3,(H,25,26)
|
|||
| InChIKey |
QZKGUNQLVFEEBA-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 80259-18-3
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
3300414, 7366243, 7856304, 8675807, 11133927, 15142450, 39365431, 49864116, 50112963, 77274000, 85858371, 88781810, 103327047, 104078011, 104223782, 106030342, 109806821, 118001726, 118058131, 124893357, 129097138, 131332031, 134224241, 134344113, 135142762, 137239553, 144043926, 162726584, 170361598, 178100759, 179071657, 223746196, 227852147, 249909195, 252565603
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Adrenergic receptor alpha-2A (ADRA2A) | Target Info | Inhibitor | [2] |
| Adrenergic receptor alpha-2B (ADRA2B) | Target Info | Inhibitor | [2] | |
| Adrenergic receptor alpha-2C (ADRA2C) | Target Info | Antagonist | [2], [3] | |
| KEGG Pathway | cGMP-PKG signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Panther Pathway | Alpha adrenergic receptor signaling pathway | |||
| Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Reactome | Adrenoceptors | |||
| Adrenaline signalling through Alpha-2 adrenergic receptor | ||||
| Adrenaline,noradrenaline inhibits insulin secretion | ||||
| G alpha (i) signalling events | ||||
| G alpha (z) signalling events | ||||
| Surfactant metabolism | ||||
| WikiPathways | Monoamine GPCRs | |||
| GPCRs, Class A Rhodopsin-like | ||||
| Platelet Aggregation (Plug Formation) | ||||
| Integration of energy metabolism | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3930). | |||
| REF 2 | Structure-activity relationship of quinoline derivatives as potent and selective alpha(2C)-adrenoceptor antagonists. J Med Chem. 2006 Oct 19;49(21):6351-63. | |||
| REF 3 | Pharmacological characterization and CNS effects of a novel highly selective alpha2C-adrenoceptor antagonist JP-1302. Br J Pharmacol. 2007 Feb;150(4):391-402. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.